Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Maternal health wikipedia , lookup
Health equity wikipedia , lookup
Fetal origins hypothesis wikipedia , lookup
Reproductive health wikipedia , lookup
Rhetoric of health and medicine wikipedia , lookup
Public health genomics wikipedia , lookup
Association of Public Health Laboratories wikipedia , lookup
March of Dimes Foundation Office of Government Affairs 1401 K Street, NW Suite 900A Washington, DC 20005 Telephone (202) 659-1800 Fax (202) 296-2964 February 2, 2015 marchofdimes.com nacersano.org The Honorable Margaret Hamburg, MD Commissioner Food and Drug Administration U.S. Department of Health and Human Services 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2011-D-0360 Dear Dr. Hamburg, The March of Dimes, a unique partnership of scientists, clinicians, parents, members of the business community and other volunteers affiliated with chapters in every state, the District of Columbia and Puerto Rico, appreciates this opportunity to submit comments regarding the Food and Drug Administration’s (FDA) Draft Guidance, Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs), as published in the Federal Register on October 3, 2014. As an organization committed to the health and wellbeing of women, infants, children, and families, the March of Dimes commends the FDA for its effort to ensure that the diagnostic tests offered to patients are safe, effective and accurate. The March of Dimes would like to urge the agency to direct special attention to the appropriate balance among safety, efficacy, innovation, and timeliness, as well as to the particular implications of this proposal for newborn screening tests. A Balance Must Be Established Throughout its 77 year history, the March of Dimes has repeatedly played a central role in the development of lifesaving tests and products. Founded by President Franklin Delano Roosevelt to develop a vaccine for polio, the March of Dimes went on from achieving that goal to funding research that has contributed to numerous additional tests and drugs, ranging from screenings for devastating newborn metabolic disorders to surfactant for premature infants’ lungs. We therefore have a strong interest in developing innovative products to improve patients’ health and bringing them to patients expeditiously as well as ensuring the safety, reliability and effectiveness of those products. The FDA faces a significant challenge in striking the appropriate balance among these goals. The March of Dimes expects that the coming years will witness the development of an array of new screening and diagnostic tests that could transform the field of maternal and child health. The March of Dimes is currently completing the establishment of a $75 million dollar network of Prematurity Research Centers to pursue a comprehensive research agenda on the causes, detection and prevention of preterm birth. It is our full expectation that this investment will result in groundbreaking tests and therapies that will revolutionize our understanding of both normal pregnancy, labor and delivery and also the conditions of pregnancy that can result in poor birth outcomes. As these new tests and products are developed, we will have a keen interest in seeing they are commercialized and adopted as quickly as possible to save lives and improve patient health. We are also, however, committed to demonstrating their safety and validity to the FDA’s satisfaction. It is therefore incumbent upon all parties to work together in designing a system that allows us to achieve all of these goals in an expeditious manner. Beyond the March of Dimes’ own research, the coming years are expected to see the development of new tests and products on a range of other maternal and child health issues, many of which have a profound impact on patients’ health and lives. The field of fertility and reproductive health research will likely see advances in tests that predict a couple’s ability to conceive, and in the health and viability of the embryo and fetus at various stages of development. We look forward to the development of new tests for neonates suffering from prematurity, low birthweight, birth defects and other conditions that result in long stays in Neonatal Intensive Care Units. The advance of “precision medicine” may allow us to predict which newborns will experience adverse reactions to certain medications, thereby averting devastating health consequences. Each of these has the potential to transform the lives and health of individuals and families. The March of Dimes would therefore like to express our commitment to working closely with the FDA to ensure that any regulatory framework for LDTs promotes patient health through a rigorous but timely process. Our patients need and deserve tests and therapies that are safe and effective, but also made available to them with all deliberate speed. Newborn Screening Tests Require Special Consideration The March of Dimes would like to draw the FDA’s attention to the particular implications the new LDT framework could have for newborn screening programs. As the agency is aware, every infant born in the U.S. is tested for over two dozen genetic, metabolic, hormonal and functional conditions that, if left untreated, can cause disabilities, developmental delays, illnesses or even death. If diagnosed early, many of these disorders can be managed successfully. In general, the bloodspots collected from newborns are sent to public health laboratories, which perform the required screening. Many newborn screening tests started out as LDTs, and some remained LDTs for many years before a commercial version was developed. The proposed framework leaves unanswered a number of key questions about how LDTs for newborn screening might be classified or regulated. Classification of newborn screening tests should be stated explicitly. It is unclear how FDA would classify newborn screening tests, and whether they might qualify as either rare tests or LDTs for unmet needs. While newborn screening identifies rare disorders, they are hardly rare tests under the FDA’s proposed threshold of 4,000 individuals since they are performed on millions of newborns each year. It is possible that certain newborn screening tests might qualify as LDTs for unmet needs. For example, while the HHS Secretary accepted the recommendation of her Advisory Committee on Heritable Diseases in Newborns and Children for universal newborn screening for Severe Combined Immunodeficiency (SCID) in 2011, the FDA only approved a commercial test for SCID in December 2014. Prior to that, SCID testing was performed utilizing only LDTs. Requiring each public health laboratory to submit its newborn screening tests individually may represent a significant burden and interfere with testing. Public health laboratories, which often operate in an environment of constrained staff and resources, may face unique challenges in submitting to FDA a list of every LDT in use, much less validating data for them. In the case of newborn screening, it is common for labs to share information and utilize the same LDT formulation. Under the FDA’s proposed framework, however, each public health laboratory would be required to report its LDTs individually, and potentially to submit data for approval. If a laboratory were unable to complete the FDA’s reporting requirements, it is further unclear if they would be in violation of the FDA’s rules to continue the state-mandated newborn screening. The March of Dimes urges the agency to explore solutions that would address the special challenges faced by public health laboratories with regard to newborn screening in ways that will not interrupt these critical tests. FDA should designate a grace period for LDTs after a commercial test becomes available. As noted above, many newborn screening programs use LDTs for an extended period of time before a commercial version of the test is approved by FDA. The agency notes in the guidance that, “…once FDA clears or approved an IVD for the same intended use, FDA will no longer consider the LDT to be an “LDT for Unmet Needs.”” The agency should state clearly a time period within which laboratories will be expected to shift to the commercial product. Because commercial tests may be more expensive than LDTs, such changes may have implications for newborn screening program budgets that must be addressed through the state’s legislative process. Again, there is the potential for the FDA’s approach to interrupt these critical statebased testing systems if the downstream implications are not fully considered by the FDA. The March of Dimes appreciates the opportunity to share our views on this important draft guidance. If we may provide further information or otherwise be of assistance, please contact James Gelfand, Director of Federal Affairs, at 202-659-1800 or [email protected]. Sincerely, Dr. Jennifer L. Howse President